The stem cell origination of the clonal process in chronic myeloproliferative disorders (CMPDs) is well established. In chronic myelogenous leukemia (CML), the primary genetic process has been characterized. However, current information regarding the mechanisms of phenotypic diversity among the CMPD and the downstream effects of the cbromosomal translocation in CML remains inconclusive. In this report, the current understanding regarding erythrocytosis in polycythemia vera (PV), thrombocytosis in essential thrombocythemia (ET), bone marrow fibrosis (BMF) in agnogenic myeloid metaplasia (AMM), and the connection between the genetic alteration and cellular transformation in CML will be discussed.
|Original language||English (US)|
|Number of pages||6|
|Journal||Seminars in Hematology|
|Issue number||SUPPL. 2|
|State||Published - Jan 28 1999|
ASJC Scopus subject areas